biology stocks are the next frontier

About this video

• Video Title: biology stocks are the next frontier
• Channel: Antonio Linares
• Speakers: Antonio Linares
• Duration: 00:41:32

Overview

This video presents the argument that the biology sector, particularly life extension and healthspan, is poised to become the next major investment frontier, surpassing previous successes in tech. The speaker outlines how advancements in AI are revolutionizing biology by enabling rapid and cost-effective reading, interpretation, and writing of biological data. This convergence is creating new horizontal platforms and an "ontology" (an AI model trained on proprietary biological data) that can predict and personalize interventions for extended health and lifespan. The video maps out the value chain from atoms to clinical outcomes, categorizing companies into those focused on the "read" and "write" layers, and discusses the importance of distribution and incentives in this emerging market.

Key takeaways

• The Next Frontier is Biology: The speaker posits that advancements in biology, driven by AI, will be significantly larger than previous tech booms like AMD, Palantir, and Tesla.
• AI Revolutionizing Biology: AI's ability to "read, interpret, and write" biological data (proteome, epigenome, genome) is improving exponentially, while costs are collapsing. This enables personalized "life extension per token."
• Value Chain: Atoms to Outcomes: The biological value chain spans from fundamental atoms and chemistry to complex biological processes and finally to clinical outcomes, with AI connecting these stages.
• Read and Write Layers: The industry is segmented into companies focused on reading biological data (e.g., Nautilus, Tempus, Caris) and those focused on writing or intervening in biological processes (e.g., ImmunityBio, Nervgen, Parabilis).
• Ontology is Key: The most valuable asset will be the "ontology"—a sophisticated AI model trained on vast, proprietary biological data—which drives predictive insights and personalized healthspan extension.
• Distribution and Incentives Matter: Companies that own the direct customer relationship and have incentives aligned with long-term health (like HIMS) are strategically positioned, unlike traditional healthcare models.
• Longevity as a Service: The future of healthcare is shifting towards "longevity as a service," where interventions are focused on optimizing health and extending lifespan, attracting significant consumer spending.

An "ontology," as described in the video, refers to a sophisticated AI model built using extensive proprietary biological data. These models act as digital twins of biological reality, enabling them to learn and make predictions.

It is considered crucial for future value creation because:

• Predictive Capabilities: Ontologies can predict what interventions a person needs to extend their lifespan and healthspan.
• Data Integration: They are able to integrate and interpret vast amounts of biological data (from the "read" layer) that a human mind cannot process.
• Personalized Interventions: By analyzing an individual's biomarkers and their response to interventions, the ontology can guide "write" layer actions for optimal health outcomes.
• Competitive Advantage: Ontologies built on unique, high-quality data offer a significant advantage, as they are difficult to replicate and can lead to superior predictive accuracy, thereby driving pricing power and value.

Here are the stocks mentioned in the video along with brief comments from the transcript:

• AMD: Speaker was an early investor, went long at $4.2 per share in 2016. Considered a "great pick" that changed the speaker's life.
• Palantir (Paluntu): Speaker was an early investor, went long at $7 per share in 2022. Considered a "great pick" that changed the speaker's life.
• Tesla: Speaker went long in 2016 at $13 per share. Considered a "great pick" that changed the speaker's life.
• Nautilus Biotechnology: Reads the proteome; has a technology called iterative mapping. Considered "very hard to replicate."
• Tempus: Performs molecular reads, particularly strong in oncology tests, providing molecular data correlated to outcomes. Operates at scale but may lack depth compared to Caris.
• Caris Life Sciences (Ticker: $C AI): Performs molecular reads, deeper genetic level than Tempus, focusing on oncology data linked to outcomes. Gets a deeper read (full exome) compared to Tempus. Producing cash but operates at less scale than Tempus.
• Recursion Pharmaceuticals (Ticker: RXRX): A "generative AI drug machine" that maps atoms to biology. Handles wet lab complexity, produces data for AI models, and can fine-tune drugs to lower toxicity and enhance efficacy. Considered "very hard to replicate."
• HIMS: Described as a "Costco for biomarkers" and a D2C (Direct-to-Consumer) distribution layer in healthcare infrastructure. Owns the customer relationship and has incentives aligned with optimizing health.
• ImmunityBio (Ticker: IBRX): Reboots the immune system by leveraging IL-15. Described as a "platform" rather than just a drug, potentially foundational for longevity. Speaker is an investor.
• Mink Therapeutics (Ticker: INKT): Leverages a third, "abandoned" branch of the immune system with extraordinary properties, complementary to ImmunityBio. Uses invariant natural killer T-cells (INKTs).
• Nervgen: Focuses on nervous system repair, developing a peptide (MPG 291) for axonal repair. Potentially a foundational platform for nervous system health.
• Parabilis Medicines: Developing a technology called "helicons" (stapled helical peptides) that can reach flat, intracellular targets, addressing previously "undruggable" disease-driving proteins. Aims to fix errors in protein networks.